navenibart

Phase 3Small molecule

AAstria Therapeutics, Inc.

navenibart is one of 4 small molecule programs targeting Hereditary Angioedema (HAE). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary Angioedema (HAE)Active, not recruiting

Hereditary Angioedema (HAE)Phase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Hereditary Angioedema (HAE)

#DrugCompanyPhaseTrials

Dawnzera (autoinjector)

Ionis Pharmaceuticals

Phase 3

1 2

Deucrictibant

PPharvaris Netherlands B.V.

Phase 3

1 3

ADX-324

AADARx Pharmaceuticals, Inc.

Phase 3

1 4

navenibart

AAstria Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Hereditary Angioedema (HAE)

NCT06842823

Clinical

Trials by Indication[1]

Hereditary Angioedema (HAE)2 trials

A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants With Hereditary Angioedema - ORBIT-EXPANSE

Enrolling by invitation·AAstria Therapeutics, Inc.·Phase 3·NCT07204938·145 enrolled

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)

Active, not recruiting·AAstria Therapeutics, Inc.·Phase 3·NCT06842823·157 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for navenibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — navenibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for navenibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astria Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAstria Therapeutics, Inc.

navenibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Hereditary Angioedema (HAE)2 trials

References

Drug Info

Quick Facts

Related News